.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
AstraZeneca
Federal Trade Commission
Mallinckrodt
Deloitte
Dow
Express Scripts
Boehringer Ingelheim
Accenture
Baxter

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,651,698

« Back to Dashboard

Which drugs does patent 7,651,698 protect, and when does it expire?


Patent 7,651,698 protects ORAVIG and is included in one NDA.

This patent has twenty patent family members in fourteen countries.

Summary for Patent: 7,651,698

Title:Prolonged release bioadhesive therapeutic systems
Abstract:The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. This bioadhesive therapeutic system comprises quantities of natural proteins representing 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.
Inventor(s): Aiache; Jean-Marc (Paris, FR), Costantini; Dominique (Paris, FR), Chaumont; Christine (Paris, FR)
Assignee: Bioalliance Pharma (Paris, FR)
Application Number:11/113,072
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Midatech Pharma UsORAVIGmiconazoleTABLET;BUCCAL022404-001Apr 16, 2010RXYesYes► Subscribe► SubscribeTREATMENT OF OROPHARYNGEAL CANDIDIASIS► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,651,698

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France01 09811Jul 23, 2001

Non-Orange Book Patents for Patent: 7,651,698

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,916,485 Prolonged release bioadhesive therapeutic systems► Subscribe
8,518,442Prolonged release bioadhesive therapeutic systems► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,651,698

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China101524337► Subscribe
Canada2455633► Subscribe
China1547464► Subscribe
Cyprus1108796► Subscribe
Cyprus1107828► Subscribe
Germany60222557► Subscribe
Germany60229456► Subscribe
Denmark1408911► Subscribe
Denmark1792610► Subscribe
European Patent Office1408911► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Covington
Johnson and Johnson
Daiichi Sankyo
UBS
Accenture
Citi
Argus Health
Cantor Fitzgerald
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot